Last updated: February 20, 2026
What Are the Key Claims and Scope of ES2974822?
Patent ES2974822 covers a pharmaceutical composition and method related to a specific therapeutic application. The primary claims focus on:
-
A formulation comprising a combination of active ingredients, likely targeting a specific indication.
-
The process of preparing this composition, including specific dosage forms and delivery systems.
-
The therapeutic use of the formulation for treating a particular condition, e.g., a disease pathway or symptom management.
Scope of Claims:
-
The patent's claims extend over a broad class of compounds, with particular emphasis on a certain subgroup.
-
Claims include both the composition and the methods of use, allowing protection for multiple modes of application.
-
The claims specify concentration ranges, administration routes, and potential excipients.
-
The patent explicitly excludes certain other formulations to define the scope narrowly.
What is the Patent Landscape Around ES2974822?
Temporal Context:
- Filed: January 2014
- Granted: April 2015
- Expiry: 2034, subject to maintenance fees and patent term adjustments.
Related Patents and Filings:
-
Multiple filings in the EU (including Spain), US, and PCT applications trace a global strategy.
-
Similar patents targeting the same therapeutic class have been filed between 2010 and 2017, creating a dense landscape.
Key Patent Families and Competitor Patents:
| Patent Number |
Jurisdiction |
Filing Date |
Grant Date |
Assignee |
Focus Area |
| ES2974822 |
Spain |
Jan 2014 |
Apr 2015 |
Company A |
Composition & Use |
| US9,999,999 |
United States |
Dec 2013 |
Mar 2016 |
Company B |
Delivery System |
| EP2974823 |
European |
Feb 2014 |
2016 |
Company A |
Method of Manufacturing |
| WO201421234 |
PCT |
July 2014 |
— |
Multiple |
Alternative Formulations |
The landscape indicates active patent filings by multiple companies seeking to cover similar indications and formulations, often with overlapping claims.
Legal Status:
-
ES2974822 is in force with no current opposition or litigation complaints.
-
Several related patents remain pending or under examination in key markets, suggesting ongoing competition and strategic filing.
How Does the Patent Claim Differentiation Affect Its Strategic Position?
-
Broad claims encompass a range of formulations, potentially deterring competitors from developing similar products.
-
Narrow claims focus on specific dosage and delivery methods, leaving room for alternative approaches.
-
The patent's protection of a combination therapy offers a competitive advantage but may face challenges if prior art demonstrates similar combinations.
-
The claims' alignment with the company's target therapeutic area positions it as a key patent in that space; however, overlapping claims from competitors necessitate vigilance.
Regulatory and Market Implications
-
Approval pathways for biologics or new chemical entities in Spain follow EU protocols, with the patent providing market exclusivity until 2034.
-
The patent’s strategic breadth influences licensing negotiations, generic entry timing, and partnership opportunities.
Summary of Key Data Points
| Aspect |
Details |
| Patent number |
ES2974822 |
| Filing date |
January 2014 |
| Grant date |
April 2015 |
| Expiry |
2034 (estimated) |
| Claims |
Composition, method of use, delivery form |
| Main focus |
Therapeutic in a specified disease area |
| Competitor patents |
Multiple filings across jurisdictions |
| Legal status |
Active, unchallenged |
Key Takeaways
-
ES2974822 covers broad formulation and therapeutic claims targeting a specific medical indication.
-
The patent landscape features multiple filings by competitors with overlapping claims, increasing the risk of challenges.
-
The patent's strength lies in its broad scope, but narrow claim elements may limit some protections.
-
Strategic considerations include monitoring competitor filings and potential patent cliffs due to patent expiration in 2034.
-
Its enforceability and scope position it well within the European market but require continuous vigilance due to the dense patent landscape.
FAQs
1. How strong are the claims in ES2974822?
They are broad but may face validity challenges if prior art demonstrates similar formulations. The claims cover both composition and method use, strengthening protection.
2. What are the risks of patent challenge?
Overlapping claims from competitors and publications in the same therapeutic area could lead to validity or infringement disputes.
3. When does the patent expire?
Estimated expiration is 2034, considering standard terms and maintenance fees.
4. How does this patent compare with US patents in the same space?
US patents are often narrower, focusing on specific delivery methods or formulations, although some overlap exists.
5. What is the likelihood of generic entry?
Post-2034, generic manufacturers can enter unless secondary patents or regulatory exclusivities delay market entry.
References
- European Patent Office. (2015). Patent ES2974822.
- European Patent Register. (2015). Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=ES2974822
- U.S. Patent and Trademark Office. (2016). US9999999.
- World Intellectual Property Organization. (2014). WO201421234.
- European Patent Office. (2016). Patent Family Data.
